Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06982105 · ClinicalTrials.gov registry record · Phase 4

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections

A Phase 4 study of Septic Arthritis and Methicillin-resistant Staphylococcus Aureus, sponsored by Indiana University.

Recruiting
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT06982105: Recruiting Phase 4 study of Septic Arthritis and Methicillin-resistant Staphylococcus Aureus, sponsored by Indiana University.

NCT06982105 is a Phase 4 study of Septic Arthritis and Methicillin-resistant Staphylococcus Aureus that is actively recruiting participants, run by Indiana University. The registered enrollment target is 100 participants, below the 225-participant average among 6 other Septic Arthritis trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06982105, a Phase 4 study of Septic Arthritis and Methicillin-resistant Staphylococcus Aureus, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if trimethoprim-sulfamethoxazole (TMP-SMX) works to treat invasive infections due to methicillin-resistant Staphylococcus aureus (MRSA) in children. It will also learn about the safety of TMP-SMX in the treatment of children with invasive MRSA infections. The main questions it aims to answer are: -Is TMP-SMX effective at successfully treating children with invasive infections due to MRSA? What are the side effects of TMP-SMX in children taking it for invasive infections due to MRSA? Researchers will compare TMP-SMX to a clindamycin (a commonly prescribed antibiotic for the treatment of MRSA in children) to see if TMP-SMX works better, worse or the same as clindamycin for children with invasive infections due to MRSA. Participants will: Take TMP-SMX or clindamycin for the treatment of their invasive infection due to MRSA. Will follow up with the provider treating their invasive infection at the discretion of the treating provider. Keep a diary of their symptoms and any side effects of the medicine

Primary Outcome

Compare number of participants with treatment success vs. failure at 6 months post hospitalization

Interventions

  • DRUG Trimethoprim Sulfamethoxazole

Study Locations (1)

Indiana

  • Riley Hospital for Children - Indianapolis

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-05-20
Est. Completion 2027-06
Phase Phase 4
Indiana University

890 total trials

What NCT06982105 shows while recruiting

NCT06982105 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 225-participant average among 6 other Septic Arthritis trials with a reported enrollment target (56% lower).

The record links to 9 conditions, with Septic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Trimethoprim Sulfamethoxazole is the first listed.

NCT06982105 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT06982105 about?

NCT06982105 is a clinical study titled "Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections". The goal of this clinical trial is to learn if trimethoprim-sulfamethoxazole (TMP-SMX) works to treat invasive infections due to methicillin-resistant Staphylococcus aureus (MRSA) in children. It will also learn about the safety of TMP-SMX in the treatment of children with invasive MRSA infections. ...

What is the current status of trial NCT06982105?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-05-20. Estimated completion is 2027-06.

What conditions does trial NCT06982105 study?

This clinical trial studies the following conditions: Septic Arthritis, Methicillin-resistant Staphylococcus Aureus, Osteomyelitis Acute, Orbital Cellulitis, Facial Cellulitis.

What interventions are being tested in trial NCT06982105?

The interventions under investigation include: Trimethoprim Sulfamethoxazole (DRUG).

Who is sponsoring clinical trial NCT06982105?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06982105 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Septic Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06982105, the US trial registry maintained by the National Library of Medicine. NCT06982105 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.